Let's Talk Risk! Podcast

Where MedTech professionals gain clarity and confidence to navigate complex decisions.

Let’s Talk Risk! brings together MedTech leaders and practitioners for thoughtful conversations on the challenges that shape risk, quality, innovation, and leadership. With 150+ episodes and more than 30K downloads, it helps professionals gain the clarity and confidence to lead through complex decisions. naveenagarwalphd.substack.com

  1. 3d ago

    LTR 167: Making AI Work in MedTech QMS

    Summary “First you have to understand the technology, what the technology does, what it's capable of, and you have to understand its limitations.” Artificial intelligence is rapidly changing how medical device companies operate. From complaint handling and nonconformance analysis to CAPA management and technical documentation, the opportunities for efficiency are substantial. But how do we ensure these new capabilities deliver reliable results without introducing unacceptable risks? In this episode of the Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Terry Irwin, Senior Distinguished Engineer at Edwards Lifesciences, about the practical realities of implementing AI within medical device quality management systems. We explore why understanding AI’s capabilities and limitations must come before deployment, how risk-based decisions can guide validation and human oversight, and why quality professionals have an opportunity to lead this transformation. Listen to the full 25-minute podcast or jump to a section of interest listed below. Chapters 00:00 AI’s expanding role in MedTech quality 02:08 Understanding AI capabilities and limitations 06:04 Risk-based validation and implementation decisions 08:46 Complaint triage, nonconformance analysis, and CAPA 13:38 Building a risk-based decision framework 17:52 AI literacy, new skills, and opportunities 21:16 ChatGPT, Copilot, Gemini, and enterprise adoption strategies 25:51 Understanding AI and leading the future of MedTech quality If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter. Suggested links: LTR: AI-Based Virtual Audits. LTR: Building a MedTech Career in the Age of AI. LTR: LTR Risk Coach - AI-Powered Decision Support Tool. Key Takeaways * Beyond the AI hype: Why organizations must understand what AI can—and cannot—reliably do before introducing it into regulated processes. * AI in quality operations: Opportunities to improve complaint triage, nonconformance trending, CAPA analysis, and technical documentation. * Risk-based validation: How a structured decision-tree approach can help determine when AI systems require validation, verification, or human review. * The reliability challenge: Why evaluating AI performance requires understanding data completeness, output accuracy, and the consequences of incorrect decisions. * Human oversight and accountability: The importance of reviewing AI-generated information, particularly when it becomes part of auditable quality records. * A new leadership opportunity: Why AI literacy, software knowledge, and risk management expertise are becoming increasingly valuable skills for quality professionals. Keywords Artificial Intelligence, MedTech, Quality Management Systems, AI Validation, Risk-Based Decision Making, Human Oversight, Complaint Management, CAPA, AI Governance, Quality Leadership About Terry Irwin Terry Irwin is a Senior Distinguished Engineer at Edwards Lifesciences, with more than 25 years of experience in medical device quality, engineering, and regulatory compliance. His career spans leadership and technical roles at Edwards Lifesciences, Nuvaira, Boston Scientific, and CIVCO Medical Solutions, with extensive experience in design controls, risk management, quality systems, software validation, and product development. Terry currently serves in a quality leadership role supporting AI implementation, bringing together his background in software technology and medical device quality management to help guide responsible adoption. Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn. Disclaimer Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations. Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    LTR 167: Making AI Work in MedTech QMS
  2. Nov 6

    Executive Brief: Scaling Software as a Medical Device

    Software velocity is not simply a development challenge. It is becoming an enterprise capability. Software is increasingly driving differentiation, recurring revenue, and customer value in MedTech. But many organizations are still trying to develop and release software through operating models designed for long-cycle hardware. The result is a growing mismatch: agile software teams operating inside rigid funding models, sequential quality processes, and late-stage regulatory gates. This Executive Brief examines what it takes to close that gap—drawing on McKinsey’s analysis of the future of Software as a Medical Device (SaMD). Key highlights covered in the audio brief: * The hardware operating model does not translate cleanly to SaMD. Long development cycles, fixed requirements, and late-stage validation can undermine the speed and iterative advantage that make software valuable. * “Shift left” changes the role of Quality and Regulatory. Design controls, risk management, documentation, and compliance activities move into the development workflow rather than being performed primarily at the end. * Agile quality can create measurable capacity. The report cites substantial reductions in testing, administrative effort, and change-control cycle time—potentially releasing additional developer capacity without simply adding headcount. * Agentic AI could become part of the quality infrastructure. Specialized agents may assist with translating requirements, drafting documentation, identifying potential risks, and maintaining traceability across rapidly changing software systems. * AI remains an augmentation strategy—not an autonomous compliance function. Human quality, regulatory, clinical, and engineering experts must continue to review, validate, and make the consequential decisions. * Funding models may need to change as much as development models. Software portfolios benefit from continuous business-case review and resource allocation based on market feedback and development velocity rather than rigid multi-year investment plans. * The hardest transformation may be cultural. Embedding Quality inside agile product teams requires changes in incentives, accountability, leadership behavior, and the traditional relationship between engineering and compliance functions. Executive takeaway Scaling Software as a Medical Device requires more than faster development. It demands an operating model that integrates quality and risk management into agile workflows, uses AI to reduce compliance burdens, and supports continuous investment decisions. The competitive advantage will belong to organizations that can deliver regulated software faster without compromising safety or compliance. Keywords Software as a Medical Device (SaMD), MedTech, Agile Quality, Shift Left, Agentic AI, Design Controls, Risk Management, Regulatory Strategy, Software Lifecycle, Digital Transformation 🎧Listen to the Executive Brief for a closer look at how shift-left quality, agile operating models, and emerging agentic AI capabilities could reshape the economics and execution of Software as a Medical Device. Thanks for reading Let's Talk Risk!. If you liked this post, share with others. Note: The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis: * McKinsey & Company (2026). The future of delivering software as a medical device. McKinsey’s Life Sciences Practice. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    Executive Brief: Scaling Software as a Medical Device
  3. Oct 30

    LTR 166: Building a MedTech Career in the Age of AI

    Summary “At the end of the day, this business of getting a job, keeping a job, getting promoted is human to human.” The MedTech job market has changed. More candidates are competing for fewer well-matched opportunities, applying has become easier at scale, and artificial intelligence is beginning to reshape both how people work and how companies hire. So how do professionals stand out? In this episode of the Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Mitch Robbins, Founder and Managing Director of The Anthony Michael Group, about what he is seeing across the MedTech talent market and what professionals at every career stage can do to prepare. Mitch argues that simply submitting more applications is not enough. Candidates need to understand the problems organizations are trying to solve, communicate the outcomes they have delivered, build relationships before they need them, and become more proactive in how they manage their careers. They also discuss where AI may affect entry-level work, why AI-generated resumes can actually make candidates look more alike, how professionals should describe contributions to cross-functional projects, and what students and mid-career professionals can do now to build long-term career resilience. Listen to the full 25-minute podcast or jump to a section of interest listed below. Chapters 00:00 – The Changing MedTech Career Landscape02:42 – How AI Is Reshaping Jobs and Hiring05:04 – Why Proactive Job Searching Still Matters08:02 – Resumes: Differentiate Through Outcomes, Not Responsibilities09:16 – Positioning Yourself as a Consultant or Solution Provider13:36 – Showing Your Individual Contribution Honestly16:47 – Career Advice for Students and Mid-Career Professionals24:02 – AI, Career Resilience, and the Importance of Human Connection If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter. Suggested links: LTR: Power up your career with mentoring. LTR: Lead with empathy to grow your Quality career. LTR: LTR Risk Coach - AI-Powered Decision Support Tool. Key Takeaways * Be proactive. Applying is not enough; build direct relationships and get in front of the people making hiring decisions. * Lead with outcomes. Show what improved because of your work, not just the responsibilities you held. * Be precise about your contribution. In cross-functional work, clearly explain what you personally contributed without overstating ownership. * Build your network before you need it. Visibility and relationship equity are much more valuable when developed consistently over time. * Know the problems your audience is trying to solve. Whether you are a student, consultant, or experienced professional, relevance comes from understanding where the need is. * Learn to use AI productively. AI will keep changing work, but human connection, judgment, and demonstrated value remain critical. Keywords MedTech careers, AI and jobs, medical device recruiting, job search strategy, resume strategy, career development, professional networking, QA/RA careers, talent acquisition, career resilience About Mitch Robbins Mitch Robbins is the Founder and Managing Director of The Anthony Michael Group, an executive search firm serving MedTech, Life Sciences, EMS, CDMO, and CMO organizations. His team’s work spans critical talent needs across Regulatory Affairs, Quality Systems and Compliance, Engineering, Operations and Technical Leadership, Market Access, Reimbursement, and Business Development. Mitch has worked in executive recruiting since 2008 and previously held senior search roles within healthcare recruiting. He is also the host of The Med-Tech Talent Lab podcast. He holds a bachelor’s degree in Psychology and Business from the University of Wisconsin–Madison. Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn. Disclaimer Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations. Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    LTR 166: Building a MedTech Career in the Age of AI
  4. Oct 23

    Executive Brief: PCCPs as a Competitive Strategy

    PCCPs can turn regulatory cycle time into a competitive advantage, but only if the evidence needed to support future change is funded in advance. Predetermined Change Control Plans (PCCP) are often discussed as a regulatory mechanism for managing future device modifications—particularly for AI-enabled medical devices. But their strategic significance goes considerably further. A well-designed PCCP allows a manufacturer to establish in advance what may change, how those changes will be evaluated, and what evidence will be required before implementation. That can fundamentally change how regulatory, R&D, clinical, and financial planning interact across the product lifecycle. Key highlights covered in the audio brief: * A PCCP pre-authorizes a pathway—not unlimited change. The flexibility remains bounded by the device’s intended use, technological characteristics, safety profile, and the specific modifications included in the authorized plan. * The Modification Protocol is the operational engine. Verification methods, performance criteria, statistical thresholds, data requirements, and implementation procedures must be established before future modifications are made. * Risk has to be evaluated across modifications, not modification-by-modification. The Impact Assessment must consider how planned changes may interact and whether their cumulative effects could alter device safety or performance. * Modularity can reduce regulatory exposure. Structuring proposed modifications and their protocols independently can help prevent a concern with one proposed change from jeopardizing the broader PCCP strategy. * Evidence becomes a capital-planning issue. Having the technical ability to make an update does not mean the company has the independent clinical evidence needed to validate it. Data acquisition, validation studies, blinding, statistical analysis, and other evidence requirements may need to be funded years ahead of deployment. * The product roadmap and evidence roadmap become inseparable. Under this model, companies can only realistically pre-authorize changes they will later have the resources and data to validate. Clinical evidence therefore becomes part of innovation planning rather than something assembled after development. Executive takeaway A PCCP is not simply a faster regulatory pathway. It is an upfront agreement on what may change, how those changes will be validated, and what evidence and risk controls must be in place. Done well, it aligns product, regulatory, clinical, risk, and financial planning—and can turn regulatory cycle time into a competitive advantage. Keywords PCCP, Predetermined Change Control Plan, FDA, Regulatory Strategy, Medical Device Software, AI/ML Medical Devices, Change Control, Clinical Evidence, Risk Management, Product Lifecycle 🎧Listen to the Executive Brief for a closer look at FDA’s expectations for toxicological data, and why extraction design, analytical sensitivity, device variability, and laboratory controls can determine whether a biological safety assessment is truly defensible. Thanks for reading Let's Talk Risk!. If you liked this post, share with others. Note: The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis: * FDA (2025). Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions: Guidance for Industry and Food and Drug Administration Staff. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). * FDA (2026). 510(k) Premarket Notification Summary: EchoPAC Software Only / EchoPAC Plug-in (v211) (K261623). U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). * FDA (2026). Predetermined Change Control Plans. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). * Ford, C. (2026). ECG-MR's Clearance Shows the Value and Boundaries of a PCCP. Zaliance Medical Solutions. * Giese, J. D. (2026). PCCPs: Best Practices, FAQs, and Examples. Innolitics. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    Executive Brief: PCCPs as a Competitive Strategy
  5. Oct 16

    LTR 165: Managing Characteristics Related to Safety

    Summary “If we don’t have connections and linkages in our risk management file from top to bottom, it’s hard to manage lifecycle risk.” In this open discussion of the Let’s Talk Risk! conversation, host Naveen Agarwal explores a requirement in ISO 14971 that is often documented but not fully integrated into medical device risk management: characteristics related to safety. Too often, organizations work through the questions in ISO/TR 24971 Annex A, document their answers, and file the document away. But identifying characteristics related to safety is only useful if those characteristics can be connected to hazards, hazardous situations, risk controls, design and manufacturing activities, supplier controls, and ultimately post-market data. The discussion expands as participant Vid joins Naveen to explore usability and software examples, estimating probability of occurrence for repeatedly used devices, and the uncertainty involved in determining appropriate exposure denominators. Naveen also discusses supplier-related risk, why assumptions should be revisited as post-market evidence develops, and why risk management competence comes from combining practical experience with continued learning. Listen to the full 25-minute podcast or jump to a section of interest listed below. Chapters 00:00 – Introduction and the Open Discussion Format00:39 – What Are Characteristics Related to Safety?03:16 – Defining Safe Limits and Establishing Traceability06:19 – Connecting Post-Market Data to the Risk Management File07:47 – Usability, Software, and Safety-Critical User Actions11:01 – Post-Market Surveillance and Supplier-Related Risk13:38 – Building Risk Management Skills Early in Your Career16:03 – Estimating Probability of Occurrence for Repeated Device Use18:27 – Managing Uncertainty and Testing Your Assumptions19:21 – Are Medical Device Risks Being Underestimated?21:29 – Let’s Talk Risk as a Knowledge-Sharing Community24:50 – LTR Risk Coach and Closing Resources If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter. Suggested links: LTR: ISO 14971 Fundamentals: Characteristics related to safety. LTR: How Traceable Are Safety-Related Characteristics in Your Risk File? LTR: LTR Risk Coach - AI-Powered Decision Support Tool. Key Takeaways * Annex A is guidance, not the end product. Answering the ISO/TR 24971 questions and filing the document away does not demonstrate how characteristics related to safety are actually being managed. * Define safe limits where possible. Characteristics related to safety should have qualitative or quantitative limits where appropriate, and those limits should connect to the risk analysis and controls. * Traceability should extend in both directions. Safety characteristics should connect upward to hazards, hazardous situations, and harms, and downward into design, manufacturing, supplier, and other operational controls. * Post-market surveillance depends on that traceability. Without clearly identified characteristics and controls, complaints and other field signals become much harder to connect to changing product performance, manufacturing processes, or emerging risk. * Supplier changes can create lifecycle risk. Safety-critical supplier characteristics need meaningful connections to the finished-device risk analysis; relying only on quality agreements and supplier audits may leave important gaps. * Probability estimates require the right denominator. For repeatedly used devices, occurrence should be considered relative to meaningful opportunities for the event—not simply an easy or overly large denominator. Assumptions and uncertainty should be documented and periodically tested against post-market data. * Risk management competence develops through practice. Naveen recommends combining hands-on involvement in real risk management work with targeted training and continued investment in professional development.. Keywords ISO 14971, characteristics related to safety, risk traceability, hazard analysis, risk controls, post-market surveillance, probability of occurrence, supplier controls, lifecycle risk management, QMSR About This Open Discussion Let’s Talk Risk! open discussions are informal conversations focused on practical questions facing medical device professionals. Rather than a webinar or formal presentation, the format creates space for participants to raise questions, share experiences, and explore how risk management principles work in practice. As Naveen explains in the episode, the broader purpose of Let’s Talk Risk! is knowledge sharing and community building that helps professionals become more confident applying risk management principles. Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn. Disclaimer Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations. Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    LTR 165: Managing Characteristics Related to Safety
  6. Oct 9

    Executive Brief: What FDA is Looking For in Your Tox Data to Ensure Safety

    Robust chemical characterization is essentially the gateway to biological safety. A toxicological risk assessment is only as strong as the analytical data supporting it. FDA’s September 2026 biocompatibility town hall provided a detailed look at how the Agency is evaluating chemical characterization and toxicological evidence under ISO 10993-18. The emphasis was not simply on whether testing was performed, but whether the resulting data are sufficiently representative, sensitive, and scientifically justified to support conclusions about biological safety. That expectation reaches well beyond testing. Extraction design, analytical thresholds, device variability, unidentified chemicals, surrogate standards, supplier changes, and CRO practices can all determine whether the toxicological evidence package remains defensible. Key highlights covered in the audio brief: * Characterize the final finished device. Raw-material data may not adequately represent the chemistry of the manufactured and sterilized device because processing can introduce degradation products and manufacturing residuals. * Use extraction conditions that are both conservative and clinically relevant. FDA’s examples show that an extraction can be too weak—but it can also become artificially aggressive and generate chemicals that do not reflect actual patient exposure. * Ensure the analytical method can actually support the toxicological threshold. FDA is scrutinizing how the analytical evaluation threshold, limit of quantification, and uncertainty factors are established and justified. If the method cannot reliably detect chemicals at the required safety threshold, the toxicological conclusion becomes difficult to defend. * Account for device-to-device variability. Analytical replicates measure instrument repeatability. Extraction replicates using separate final finished devices are needed to evaluate variability in the devices themselves. * Do not eliminate variability through pooling. Combining extracts can dilute a high-result outlier and mask an intermittent manufacturing-related chemical exposure. FDA specifically cautioned against this practice. * Justify unidentified chemicals and surrogate standards. FDA expects objective scientific support for how unknown constituents are quantified and why a particular surrogate standard is appropriate. Executive takeaway Toxicological risk assessment should not be treated as an isolated report generated at the end of biocompatibility testing. It is the downstream interpretation of an evidence system that begins with the finished device and depends on how that device is manufactured, extracted, analyzed, quantified, and controlled over its lifecycle. The strongest toxicological conclusion cannot compensate for weak underlying data. Keywords Biocompatibility, toxicological risk assessment, chemical characterization, ISO 10993-18, biological safety, analytical evaluation threshold, AET, extraction replicates, CRO oversight, supplier change control 🎧Listen to the Executive Brief for a closer look at FDA’s expectations for toxicological data, and why extraction design, analytical sensitivity, device variability, and laboratory controls can determine whether a biological safety assessment is truly defensible. Thanks for reading Let's Talk Risk!. If you liked this post, share with others. Note: The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis: * FDA (2026). Biocompatibility Town Hall #2: Extractions for Conducting Chemical Analysis for Biocompatibility Assessment. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    Executive Brief: What FDA is Looking For in Your Tox Data to Ensure Safety
  7. Oct 2

    LTR 164: Susan Neadle on Combination Device Risk Management

    Summary “ISO 14971 and ICH Q9 are not competing frameworks. They are asking different questions about risk.” In this episode of the Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Susan Neadle, Principal Consultant and President of Combination Products Consulting Services, to explore what changes when medical device and pharmaceutical risk-management approaches come together in a combination product. ISO 14971 places strong emphasis on hazards, hazardous situations, harms, users, and safety. ICH Q9 approaches risk through a different lens, with a strong focus on product quality, process variability, critical quality attributes, and control strategies. Susan explains why neither perspective is sufficient by itself for a combination product—and why the real challenge is understanding the interactions among the drug, device, manufacturing process, user, environment, and lifecycle. They also discuss the work underway on ISO 24971-3, intended to provide practical guidance on integrating these approaches; how new hazards and hazardous situations can emerge from constituent-part interactions; what combination products mean for supplier controls; and the leadership judgment required when technical, business, and patient considerations converge. Listen to the full 25-minute podcast or jump to a section of interest listed below. Chapters 01:19 – What Are Combination Products?02:41 – Difference in Risk Management.05:06 – Why Meeting Specifications Is Not Enough08:40 – ISO 24971-3 and the Need for Practical Integration Guidance10:49 – Bridging Drug and Device Risk Management Mindsets13:17 – ISO 14971 and ICH Q9: Different Questions About Risk14:55 – Combined Use Systems, Interface Risks, and New Hazardous Situations18:01 – Interaction Risks Between Drugs, Devices, and Biologics19:33 – Leadership, Judgment, and Making Risk-Based Decisions22:03 – Supplier Controls and Sponsor Responsibility24:55 – Key Takeaways: Lifecycle Risk Management and Keeping the End User Safe If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter. Suggested links: LTR: Integrating purchasing controls across product lifecycle. LTR: FDA’s New Risk Lens Under QMSR. LTR: LTR Risk Coach - AI-Powered Decision Support Tool. Key Takeaways * ISO 14971 and ICH Q9 are complementary, not competing. They examine risk through different lenses, and combination products require both perspectives. * The unit of analysis becomes the combined use system. Looking separately at a drug and device can miss risks created by their interactions with each other, the user, manufacturing processes, and the use environment. * Specifications alone do not establish safety. Particularly on the device side, user interaction and lifecycle experience can reveal hazards even when the product continues to meet specification. * Interactions can create risks that do not exist within either constituent part alone. Material compatibility, degradation, adsorption, extractables and leachables, sterilization, and biologic interactions are examples discussed in the episode. * Lifecycle changes matter. Supplier changes, process changes, labeling changes, and post-market information can alter the risk picture and require reassessment of the complete system. * The sponsor owns the complete risk picture. Suppliers may have strong risk-management processes for their particular component or constituent part, but the sponsor remains responsible for understanding the complete combination product. * Risk management is not a document. It is an ongoing lifecycle process informed by the product, constituent parts, manufacturing process, users, and post-market experience. Keywords Combination products, ISO 14971, ICH Q9, ISO 24971-3, combined use systems, lifecycle risk management, supplier controls, human factors, benefit-risk assessment, post-market risk About Susan Neadle Susan Neadle MS, BS, FRAPS, FAAO, is Principal Consultant and President of Combination Products Consulting Services LLC and an internationally recognized expert in combination products, medical devices, digital health, risk management, quality, regulatory affairs, and product and process design. She brings more than 35 years of industry experience, including a 26-year career at Johnson & Johnson and leadership experience at Amgen. Susan chairs the AAMI Combination Products Steering Committee and has held leadership roles across numerous industry working groups. She is also an educator and author of The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems. Her career has included extensive work in combination-product quality and regulatory strategy, design controls, Quality by Design, criticality analysis, risk management, and lifecycle product development. Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn. Disclaimer Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations. Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    LTR 164: Susan Neadle on Combination Device Risk Management
  8. Sep 25

    Deep Dive: When the Risk Baseline and the QMS Both Break Down

    The baseline is completely broken and the iteration process is blind. FDA’s August 21, 2026 warning letter to Pensar Medical LLC illustrates a failure that goes well beyond incomplete documentation. The underlying risk-management foundation was weak. Risk-control verification remained incomplete for critical areas, and FDA reportedly found no design, process, or use-related FMEAs for the WoundPro product line. At the same time, key QMS processes were also failing. Key highlights covered in the audio: * Risk analysis was incomplete or missing. Critical risk controls remained unverified, and some products lacked the basic FMEAs required by the firm’s own procedures. * Design and software changes were poorly controlled. Multiple changes lacked adequate implementation records, including an engineering change order described simply as “clean up all code,” with no verification record showing what had actually changed. * Field corrections were not properly managed. Software rework performed in the field was not reported within the required timeframe. * CAPA was not functioning as a learning system. FDA found CAPA records with missing root-cause analysis, corrective actions, and effectiveness verification. In another case, a corrective action was never incorporated back into the risk analysis. * Post-market information was not being translated into effective action. A serious injury involving retained foam and surgical intervention was reported late and categorized as a malfunction rather than a serious injury. The central lesson is straightforward: A robust QMS needs both a reliable risk baseline and processes that continuously challenge, maintain, and improve that baseline. If the original risk analysis is weak, changes cannot be evaluated properly. If CAPA, complaint handling, change control, and post-market processes are weak, new information never strengthens the risk analysis. That is how individual weaknesses become a systemic quality failure.. Keywords: Pensar Medical, FDA Warning Letter, QMSR, ISO 13485, Risk Management, Risk Analysis, Design Change Control, CAPA, Medical Device Reporting, Quality Management System 🎧Listen to the Deep Dive for a closer look at how the Pensar warning letter shows the consequences when both risk management and the broader QMS fail to operate as a closed-loop system. Thanks for reading Let's Talk Risk!. If you liked this post, share with others. Note: The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis: * FDA (2026). Warning Letter: Lion Street Medical, d/b/a Pensar Medical LLC (CDRH-MARCS-CMS 733015). This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

    Deep Dive: When the Risk Baseline and the QMS Both Break Down

Ratings & Reviews

5
out of 5
2 Ratings

About

Let’s Talk Risk! brings together MedTech leaders and practitioners for thoughtful conversations on the challenges that shape risk, quality, innovation, and leadership. With 150+ episodes and more than 30K downloads, it helps professionals gain the clarity and confidence to lead through complex decisions. naveenagarwalphd.substack.com

You Might Also Like